HOXA9 and leukemia: Moreover, we found that the enhanced RNA binding activity of MSI2 leads to differential regulation, e.g., at Hoxa9, Ikzf2, and Myb targets, in LSCs versus LSKs, which provides a possible explanation for the differential requirement of MSI2 in leukemia compared with normal hematopoiesis.